AC Immune SA (NASDAQ:ACIU) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price objective of $23.00 for the company and are anticipating that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given AC Immune SA an industry rank of 111 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded AC Immune SA from a “sell” rating to a “hold” rating in a research note on Monday, October 16th.
COPYRIGHT VIOLATION WARNING: “Analysts Expect AC Immune SA (ACIU) to Post ($0.10) Earnings Per Share” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/21/analysts-expect-ac-immune-sa-aciu-to-post-0-10-earnings-per-share.html.
Large investors have recently modified their holdings of the business. Cohen Lawrence B bought a new position in AC Immune SA during the 2nd quarter valued at $297,000. Belpointe Asset Management LLC bought a new stake in shares of AC Immune SA during the 3rd quarter worth $571,000. Janney Montgomery Scott LLC bought a new stake in shares of AC Immune SA during the 3rd quarter worth $134,000. Wells Fargo & Company MN bought a new stake in shares of AC Immune SA during the 3rd quarter worth $111,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AC Immune SA during the 2nd quarter worth $127,000. Institutional investors and hedge funds own 19.21% of the company’s stock.
AC Immune SA Company Profile
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.